Karyopharm Therapeutics Inc [NASDAQ: KPTI] gained 15.04% or 0.2 points to close at $1.53 with a heavy trading volume of 3137408 shares. The company report on March 6, 2024 at 4:05 PM that Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company’s senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday, March 13, 2024 at 9:00 a.m. ET in Miami Beach, FL.
A live webcast of the fireside chat at the Barclays conference can be accessed under “Events & Presentations” in the Investor section of the Company’s website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.
The daily chart for KPTI points out that the company has recorded 30.77% gains over the past six months.
If we look at the average trading volume of 1.89M shares, KPTI reached to a volume of 3137408 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Karyopharm Therapeutics Inc [KPTI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KPTI shares is $5.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KPTI stock is a recommendation set at 1.57. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Karyopharm Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 19, 2023. While these analysts kept the previous recommendation, RBC Capital Mkts dropped their target price from $7 to $10. The new note on the price target was released on November 04, 2022, representing the official price target for Karyopharm Therapeutics Inc stock. Previously, the target price had yet another raise to $8, while JP Morgan analysts kept a Neutral rating on KPTI stock. On November 19, 2021, analysts decreased their price target for KPTI shares from 27 to 10.
The Average True Range (ATR) for Karyopharm Therapeutics Inc is set at 0.17, with the Price to Sales ratio for KPTI stock in the period of the last 12 months amounting to 1.21.
Trading performance analysis for KPTI stock
Karyopharm Therapeutics Inc [KPTI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.90. With this latest performance, KPTI shares dropped by -7.83% in over the last four-week period, additionally plugging by 30.77% over the last 6 months – not to mention a drop of -51.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KPTI stock in for the last two-week period is set at 62.92, with the RSI for the last a single of trading hit 65.97, and the three-weeks RSI is set at 61.32 for Karyopharm Therapeutics Inc [KPTI]. The present Moving Average for the last 50 days of trading for this stock 1.0658, while it was recorded at 1.3200 for the last single week of trading, and 1.3065 for the last 200 days.
Karyopharm Therapeutics Inc [KPTI]: A deeper dive into fundamental analysis
Karyopharm Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.32 and a Current Ratio set at 3.37.
Karyopharm Therapeutics Inc [KPTI]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Karyopharm Therapeutics Inc posted -0.3/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 18.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KPTI.
An analysis of Institutional ownership at Karyopharm Therapeutics Inc [KPTI]
The top three institutional holders of KPTI stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in KPTI stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in KPTI stock with ownership which is approximately 5.8325%.
